Gilead Sciences, Inc. $GILD Stock Position Reduced by Hantz Financial Services Inc.

Hantz Financial Services Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,043 shares of the biopharmaceutical company’s stock after selling 1,080 shares during the quarter. Hantz Financial Services Inc.’s holdings in Gilead Sciences were worth $3,109,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. One Wealth Advisors LLC boosted its position in Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after purchasing an additional 2,364 shares during the period. Ariel Investments LLC boosted its position in Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after purchasing an additional 30,630 shares during the period. Golden State Wealth Management LLC boosted its position in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 109 shares during the period. Covea Finance boosted its position in Gilead Sciences by 69.5% during the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock valued at $5,732,000 after purchasing an additional 21,200 shares during the period. Finally, Wealth Management Associates Inc. acquired a new position in Gilead Sciences during the 2nd quarter valued at approximately $255,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. BMO Capital Markets boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. Wolfe Research boosted their price objective on Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Royal Bank Of Canada boosted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $123.87.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider directly owned 110,193 shares of the company’s stock, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 71,500 shares of company stock valued at $8,336,040 over the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 1.1%

GILD opened at $119.79 on Friday. The stock’s fifty day moving average is $115.66 and its 200-day moving average is $111.57. The company has a market capitalization of $148.64 billion, a PE ratio of 23.86, a P/E/G ratio of 0.81 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.